home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Two Proteins, Pim-1 And Hepsin, May Be Useful Markers In Prostate Biopsy Specimens

 
  August, 24 2001 0:26
your information resource in human molecular genetics
 
     
CANCER CALL SHEET

US researchers propose a genetic profile for prostate cancer in this week’s Nature (Vol. 412, No. 6849, 23 Aug 2001). Arul M. Chinnaiyan and colleagues of the University of Michigan Medical School, Ann Arbor, have come up with a shortlist of genes to distinguish malignant from benign tissue.

They also find that the expression of two proteins — hepsin and pim-1 — seem to be significantly correlated with poor clinical outcome in prostate cancer, the most frequently diagnosed cancer in American men.

Screening serum for a substance called PSA has led to earlier detection of prostate cancer, but this test is prone to false positives, as the protein can be present in non-malignant conditions. Pim-1 and hepsin are associated with cells and unlikely to be found in serum. They may be more useful markers in prostate biopsy specimens.

CONTACT:

Arul M. Chinnaiyan
tel +1 734 936 1887
e-mail arul@umich.edu

(C) Nature press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.